Low resistance of Li-intercalated unfavourable electrodes is essential for the secure and quick charging required for large-scale batteries. Right here, we demonstrated that nanosized two-dimensional crystalline fragrant dicarboxylate unfavourable electrode supplies synthesized through spray drying exhibit low inside resistances at roughly 0.7 V vs Li/Li+, whereas retaining flat potential profiles. The spray-dried pattern with a hole construction is crushed into nanoflakes throughout ink preparation for electrode coating and kinds a uniform and extremely dispersed electrode construction.
The charge-discharge analysis signifies that the nanoflake pattern confirmed smaller charge-discharge polarization than the majority pattern with secure biking traits, leading to vital high-rate property enhancement. Cost-transfer resistance of the nanoflake pattern reveals the bottom worth (ca. 2.2 Ω cm2) amongst these reported for current intercalation electrodes (5.2 to 235 Ω cm2). Compared of the unfavourable electrodes, the estimated most present density with out Li deposition (ca. 316 mA cm-2) is greater than 1 order of magnitude larger than that for at present used graphite (ca. 11 mA cm-2) and can also be larger than these for high-rate oxides (137-298 mA cm-2).
The resistance-crystal correlation utilizing a number of regression evaluation predictions and its verification reveal that this low resistance is owing to an improved Li acceptability related to selective structural defects induced by the lack of included crystallized water throughout drying. The crystal aircraft uncovered by the selective structural defects is perpendicular to digital and ionic conduction instructions contained in the stable, leading to improved kinetics. Subsequently, the proposed unfavourable electrode permits secure and quick charging, with straightforward scale-up and sustainable sources.
Purposeful Genomics Approaches to Elucidate Vulnerabilities of Intrinsic and Acquired Chemotherapy Resistance
Drug resistance is a generally unavoidable consequence of most cancers remedy that ends in remedy failure and illness relapse. Intrinsic (pre-existing) or acquired resistance mechanisms could be drug-specific or be relevant to a number of medicine, leading to multidrug resistance. The presence of drug resistance is, nonetheless, tightly coupled to modifications in mobile homeostasis, which might result in resistance-coupled vulnerabilities. Unbiased gene perturbations by way of RNAi and CRISPR applied sciences are invaluable instruments to determine genotype-to-phenotype relationships on the genome scale.
Furthermore, their software to most cancers cell strains can uncover new vulnerabilities which are related to resistance mechanisms. Right here, we focus on focused and unbiased RNAi and CRISPR efforts within the discovery of drug resistance mechanisms by specializing in first-in-line chemotherapy and their enforced vulnerabilities, and we current a view ahead on which measures ought to be taken to speed up their medical translation.
Induction of ADAM10 by RT drives fibrosis, resistance, and EMT in pancreatic most cancers
Stromal fibrosis prompts pro-survival and pro-epithelial-to-mesenchymal transition (EMT) pathways in pancreatic ductal adenocarcinoma (PDAC). In affected person tumors handled with neoadjuvant stereotactic physique radiation remedy (SBRT), we discovered upregulation of fibrosis, extracellular matrix (ECM), and EMT gene signatures, which might drive therapeutic resistance and tumor invasion. Molecular, practical, and translational evaluation recognized two cell floor proteins, A disintegrin and metalloprotease 10 (ADAM10) and ephrinB2, as drivers of fibrosis and tumor development after RT. RT resulted in elevated ADAM10 expression in tumor cells, resulting in cleavage of ephrinB2, which was additionally detected in plasma.
Pharmacologic or genetic focusing on of ADAM10 decreased RT-induced fibrosis and tissue rigidity, tumor cell migration, and invasion, sensitizing orthotopic tumors to radiation killing and prolonging mouse survival. Inhibition of ADAM10 and genetic ablation of ephrinB2 in fibroblasts decreased the metastatic potential of tumor cells after RT. Stimulation of tumor cells with EphrinB2 FC-protein reversed the discount in tumor cell invasion with ADAM10 ablation. These findings signify a mannequin of PDAC adaptation that explains resistance and metastasis after radiation remedy and identifies a targetable pathway to reinforce RT efficacy.
Exogenous and endogenous sources of serine contribute to colon most cancers metabolism, development, and resistance to 5-fluorouracil
Serine is a non-essential amino acid generated by the sequential actions of phosphoglycerate dehydrogenase (PHGDH), phosphoserine aminotransferase (PSAT1), and phosphoserine phosphatase (PSPH). Elevated serine biosynthesis happens in a number of cancers and helps tumor development. Moreover, most cancers cells can harness exogenous serine to reinforce their metabolism and proliferation. Right here we examined the relative contributions of exogenous and endogenous sources of serine on the biology of colorectal most cancers (CRC). In murine tumors, Apc standing was recognized as a determinant of the expression of genes controlling serine synthesis.

In affected person samples, PSAT1 was overexpressed in each colorectal adenomas and adenocarcinomas. Combining genetic deletion of PSAT1 with exogenous serine deprivation maximally suppressed the proliferation of CRC cells and induced profound metabolic defects together with diminished nucleotide manufacturing. Inhibition of serine synthesis enhanced the transcriptional modifications following exogenous serine elimination in addition to alterations related to DNA injury.
BCAR1 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro) |
|
LV672495 |
ABM |
1.0 ug DNA |
EUR 1695.6 |
BCAR1 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro) |
|
LV672496 |
ABM |
1.0 ug DNA |
EUR 1695.6 |
Bcar1 - Rat, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|
TL709541 |
Origene Technologies GmbH |
5 µg/vial |
Ask for price |
BCAR1 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|
TL314502 |
Origene Technologies GmbH |
5 µg/vial |
Ask for price |
Bcar1 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|
TL510791 |
Origene Technologies GmbH |
5 µg/vial |
Ask for price |
Bcar3 - Rat, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|
TL706272 |
Origene Technologies GmbH |
5 µg/vial |
Ask for price |
BCAR3 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|
TL314501 |
Origene Technologies GmbH |
5 µg/vial |
Ask for price |
Bcar3 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|
TL502758 |
Origene Technologies GmbH |
5 µg/vial |
Ask for price |
Bcar1 ORF Vector (Rat) (pORF) |
|
ORF063985 |
ABM |
1.0 ug DNA |
EUR 607.2 |
BCAR1 ORF Vector (Human) (pORF) |
|
ORF016109 |
ABM |
1.0 ug DNA |
EUR 486 |
Bcar1 ORF Vector (Mouse) (pORF) |
|
ORF039734 |
ABM |
1.0 ug DNA |
EUR 607.2 |
Bcar1 ORF Vector (Mouse) (pORF) |
|
ORF039735 |
ABM |
1.0 ug DNA |
EUR 607.2 |
BCAR1 Protein Vector (Rat) (pPM-C-HA) |
|
PV255940 |
ABM |
500 ng |
EUR 1399.2 |
BCAR1 Protein Vector (Rat) (pPB-C-His) |
|
PV255938 |
ABM |
500 ng |
EUR 1399.2 |
BCAR1 Protein Vector (Rat) (pPB-N-His) |
|
PV255939 |
ABM |
500 ng |
EUR 1399.2 |
BCAR1 Protein Vector (Rat) (pPM-C-His) |
|
PV255941 |
ABM |
500 ng |
EUR 1399.2 |
BCAR1 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml. |
|
TL314502V |
Origene Technologies GmbH |
500 ul each |
Ask for price |
Bcar1 - Rat shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml. |
|
TL709541V |
Origene Technologies GmbH |
500 ul each |
Ask for price |
Bcar1 - Mouse shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml. |
|
TL510791V |
Origene Technologies GmbH |
500 ul each |
Ask for price |
BCAR1 Protein Vector (Human) (pPM-C-HA) |
|
PV064435 |
ABM |
500 ng |
EUR 973.2 |
BCAR1 Protein Vector (Mouse) (pPM-C-HA) |
|
PV158936 |
ABM |
500 ng |
EUR 1278 |
BCAR1 Protein Vector (Mouse) (pPM-C-HA) |
|
PV158940 |
ABM |
500 ng |
EUR 1278 |
BCAR1 Protein Vector (Human) (pPB-C-His) |
|
PV064433 |
ABM |
500 ng |
EUR 973.2 |
BCAR1 Protein Vector (Human) (pPB-N-His) |
|
PV064434 |
ABM |
500 ng |
EUR 973.2 |
BCAR1 Protein Vector (Human) (pPM-C-His) |
|
PV064436 |
ABM |
500 ng |
EUR 973.2 |
BCAR1 Protein Vector (Mouse) (pPB-C-His) |
|
PV158934 |
ABM |
500 ng |
EUR 1278 |
BCAR1 Protein Vector (Mouse) (pPB-N-His) |
|
PV158935 |
ABM |
500 ng |
EUR 1278 |
BCAR1 Protein Vector (Mouse) (pPM-C-His) |
|
PV158937 |
ABM |
500 ng |
EUR 1278 |
BCAR1 Protein Vector (Mouse) (pPB-C-His) |
|
PV158938 |
ABM |
500 ng |
EUR 1278 |
BCAR1 Protein Vector (Mouse) (pPB-N-His) |
|
PV158939 |
ABM |
500 ng |
EUR 1278 |
BCAR1 Protein Vector (Mouse) (pPM-C-His) |
|
PV158941 |
ABM |
500 ng |
EUR 1278 |
BCAR1 Protein Vector (Human) (pPB-His-MBP) |
|
PV326406 |
ABM |
500 ng |
EUR 973.2 |
BCAR1 Protein Vector (Human) (pPB-His-GST) |
|
PV326407 |
ABM |
500 ng |
EUR 973.2 |
BCAR1 Protein Vector (Human) (pPM-N-D-C-HA) |
|
PV326408 |
ABM |
500 ng |
Ask for price |
BCAR1 Protein Vector (Human) (pPM-N-D-C-His) |
|
PV326409 |
ABM |
500 ng |
Ask for price |
CD Lentiviral Vector |
|
LV678 |
ABM |
10 μg |
EUR 950 |
BCAN Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|
LV694345 |
ABM |
1.0 ug DNA |
EUR 1626 |
BCAN Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|
LV694349 |
ABM |
1.0 ug DNA |
EUR 1626 |
BCAN Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|
LV697117 |
ABM |
1.0 ug DNA |
EUR 818.4 |
BCAN Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|
LV697121 |
ABM |
1.0 ug DNA |
EUR 818.4 |
BCAM Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|
LV667153 |
ABM |
1.0 ug DNA |
EUR 818.4 |
BCAM Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|
LV667157 |
ABM |
1.0 ug DNA |
EUR 818.4 |
BCAS3 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|
LV623617 |
ABM |
1.0 ug DNA |
EUR 1626 |
BCAS3 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|
LV623621 |
ABM |
1.0 ug DNA |
EUR 1626 |
BCAS1 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|
LV688243 |
ABM |
1.0 ug DNA |
EUR 818.4 |
BCAS1 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|
LV688247 |
ABM |
1.0 ug DNA |
EUR 818.4 |
BCAT1 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|
LV678751 |
ABM |
1.0 ug DNA |
EUR 818.4 |
BCAT1 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|
LV678755 |
ABM |
1.0 ug DNA |
EUR 818.4 |
BCAT2 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|
LV675187 |
ABM |
1.0 ug DNA |
EUR 818.4 |
BCAT2 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|
LV675191 |
ABM |
1.0 ug DNA |
EUR 818.4 |
BCAP31 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|
LV635779 |
ABM |
1.0 ug DNA |
EUR 616.8 |
BCAP31 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|
LV635783 |
ABM |
1.0 ug DNA |
EUR 616.8 |
BCAP29 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|
LV629383 |
ABM |
1.0 ug DNA |
EUR 616.8 |
BCAP29 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|
LV629387 |
ABM |
1.0 ug DNA |
EUR 616.8 |
BCAN Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
|
LV694350 |
ABM |
1.0 ug DNA |
EUR 1626 |
BCAN Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
|
LV697122 |
ABM |
1.0 ug DNA |
EUR 818.4 |
BCAN Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|
LV707793 |
ABM |
1.0 ug DNA |
EUR 379.2 |
BCAN Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|
LV707797 |
ABM |
1.0 ug DNA |
EUR 379.2 |
BCAM Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
|
LV667158 |
ABM |
1.0 ug DNA |
EUR 818.4 |
BCAS3 Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
|
LV623622 |
ABM |
1.0 ug DNA |
EUR 1626 |
BCAS3 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|
LV702231 |
ABM |
1.0 ug DNA |
EUR 540 |
BCAS3 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|
LV702235 |
ABM |
1.0 ug DNA |
EUR 540 |
BCAS1 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|
LV702459 |
ABM |
1.0 ug DNA |
EUR 540 |
BCAS1 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|
LV702463 |
ABM |
1.0 ug DNA |
EUR 540 |
BCAS1 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|
LV702477 |
ABM |
1.0 ug DNA |
EUR 540 |
BCAS1 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|
LV702481 |
ABM |
1.0 ug DNA |
EUR 540 |
BCAS1 Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
|
LV688248 |
ABM |
1.0 ug DNA |
EUR 818.4 |
BCAT1 Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
|
LV678756 |
ABM |
1.0 ug DNA |
EUR 818.4 |
BCAT2 Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
|
LV675192 |
ABM |
1.0 ug DNA |
EUR 818.4 |
BCAP31 Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
|
LV635784 |
ABM |
1.0 ug DNA |
EUR 616.8 |
BCAP29 Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
|
LV629388 |
ABM |
1.0 ug DNA |
EUR 616.8 |
BCAN Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|
LV707798 |
ABM |
1.0 ug DNA |
EUR 379.2 |
BCAP31 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|
LV707799 |
ABM |
1.0 ug DNA |
EUR 379.2 |
BCAP31 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|
LV707803 |
ABM |
1.0 ug DNA |
EUR 379.2 |
BCAS3 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|
LV702236 |
ABM |
1.0 ug DNA |
EUR 540 |
BCAS1 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|
LV702464 |
ABM |
1.0 ug DNA |
EUR 540 |
BCAS1 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|
LV702482 |
ABM |
1.0 ug DNA |
EUR 540 |
BCAS2P1 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|
LV719615 |
ABM |
1.0 ug DNA |
Ask for price |
BCAS2P1 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|
LV719619 |
ABM |
1.0 ug DNA |
Ask for price |
BCAS2P2 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|
LV719621 |
ABM |
1.0 ug DNA |
Ask for price |
BCAS2P2 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|
LV719625 |
ABM |
1.0 ug DNA |
Ask for price |
BCAS2P3 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|
LV719627 |
ABM |
1.0 ug DNA |
Ask for price |
BCAS2P3 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|
LV719631 |
ABM |
1.0 ug DNA |
Ask for price |
BCAP31 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|
LV707804 |
ABM |
1.0 ug DNA |
EUR 379.2 |
BCAS2P1 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|
LV719620 |
ABM |
1.0 ug DNA |
Ask for price |
BCAS2P2 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|
LV719626 |
ABM |
1.0 ug DNA |
Ask for price |
BCAS2P3 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|
LV719632 |
ABM |
1.0 ug DNA |
Ask for price |
Cas9 Nickase Lentiviral Vector |
|
K005 |
ABM |
10 ug |
EUR 135 |
|
Description: N/A |
dCas9-KRAB Lentiviral Vector |
|
K203 |
ABM |
10 ug |
EUR 165 |
|
Description: N/A |
Cas9 Nuclease Lentiviral Vector |
|
K002 |
ABM |
10 ug |
EUR 135 |
|
Description: N/A |
dCas9-DNMT3A Lentiviral Vector |
|
K091 |
ABM |
10 µg, Titer: N/A |
EUR 395 |
|
Description: N/A |
dCas9-TET1CD Lentiviral Vector |
|
K096 |
ABM |
10 µg, Titer: N/A |
EUR 395 |
|
Description: N/A |
Green Kit. Baculovirus GFP vector. |
|
K20 |
AB Vector LLC |
1 Kit |
EUR 695 |
- Kit for baculovirus protein expression
|
|
Description: Protein expression |
ProGreen. Baculovirus GFP marker vector. |
|
A1 |
AB Vector LLC |
25 ul |
EUR 420 |
- Linearized baculovirus vector DNA
|
|
Description: Protein expression |
Bcar1 sgRNA CRISPR Lentivector set (Rat) |
|
K6802201 |
ABM |
3 x 1.0 ug |
EUR 406.8 |
BCAN Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-C-term-HA) |
|
LV694346 |
ABM |
1.0 ug DNA |
EUR 1626 |
BCAN Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-C-term-HA) |
|
LV697118 |
ABM |
1.0 ug DNA |
EUR 818.4 |
BCAM Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-C-term-HA) |
|
LV667154 |
ABM |
1.0 ug DNA |
EUR 818.4 |
BCAR1 sgRNA CRISPR Lentivector set (Human) |
|
K0173301 |
ABM |
3 x 1.0 ug |
EUR 406.8 |
Bcar1 sgRNA CRISPR Lentivector set (Mouse) |
|
K3814401 |
ABM |
3 x 1.0 ug |
EUR 406.8 |
Cas9 Double Mutant Lentiviral Vector |
|
K012 |
ABM |
10 ug |
EUR 395 |
|
Description: N/A |
Bcar1 - Mouse, 4 unique 29mer shRNA constructs in retroviral RFP vector |
|
TF510791 |
Origene Technologies GmbH |
5 µg/vial |
Ask for price |
BCAS3 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-C-term-HA) |
|
LV623618 |
ABM |
1.0 ug DNA |
EUR 1626 |
BCAS1 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-C-term-HA) |
|
LV688244 |
ABM |
1.0 ug DNA |
EUR 818.4 |
BCAT1 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-C-term-HA) |
|
LV678752 |
ABM |
1.0 ug DNA |
EUR 818.4 |
BCAT2 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-C-term-HA) |
|
LV675188 |
ABM |
1.0 ug DNA |
EUR 818.4 |
BCAP31 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-C-term-HA) |
|
LV635780 |
ABM |
1.0 ug DNA |
EUR 616.8 |
BCAP29 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-C-term-HA) |
|
LV629384 |
ABM |
1.0 ug DNA |
EUR 616.8 |
BCAN Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro) |
|
LV694347 |
ABM |
1.0 ug DNA |
EUR 1695.6 |
BCAN Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro) |
|
LV694348 |
ABM |
1.0 ug DNA |
EUR 1695.6 |
BCAN Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro) |
|
LV697119 |
ABM |
1.0 ug DNA |
EUR 888 |
BCAN Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro) |
|
LV697120 |
ABM |
1.0 ug DNA |
EUR 888 |
BCAN Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-C-term-HA) |
|
LV707794 |
ABM |
1.0 ug DNA |
EUR 379.2 |
BCAM Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro) |
|
LV667155 |
ABM |
1.0 ug DNA |
EUR 888 |
BCAM Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro) |
|
LV667156 |
ABM |
1.0 ug DNA |
EUR 888 |
BCAS3 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro) |
|
LV623619 |
ABM |
1.0 ug DNA |
EUR 1695.6 |
BCAS3 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro) |
|
LV623620 |
ABM |
1.0 ug DNA |
EUR 1695.6 |
BCAS3 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-C-term-HA) |
|
LV702232 |
ABM |
1.0 ug DNA |
EUR 540 |
BCAS1 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-C-term-HA) |
|
LV702460 |
ABM |
1.0 ug DNA |
EUR 540 |
BCAS1 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-C-term-HA) |
|
LV702478 |
ABM |
1.0 ug DNA |
EUR 540 |
BCAS1 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro) |
|
LV688245 |
ABM |
1.0 ug DNA |
EUR 888 |
BCAS1 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro) |
|
LV688246 |
ABM |
1.0 ug DNA |
EUR 888 |
BCAT1 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro) |
|
LV678753 |
ABM |
1.0 ug DNA |
EUR 888 |
BCAT1 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro) |
|
LV678754 |
ABM |
1.0 ug DNA |
EUR 888 |
BCAT2 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro) |
|
LV675189 |
ABM |
1.0 ug DNA |
EUR 888 |
Each lack of PSAT1 and elimination of serine from the weight loss plan had been essential to suppress CRC xenograft development and improve the anti-tumor exercise of 5-fluorouracil (5-FU). Limiting endogenous and exogenous serine in vitro augmented 5-FU induced cell dying, DNA injury, and metabolic perturbations, probably accounting for the noticed anti-tumor impact. Collectively, our outcomes counsel that each endogenous and exogenous sources of serine contribute to CRC development and resistance to 5-FU.